Royal Prince Alfred Hospital ( Site 0005)(7.5 mi away)Contact
+98 other location
The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus
valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The
primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is
demonstrated, that LET is superior to VGCV, in preventing CMV disease through 52 weeks
Placebo to ACV,
Placebo to LET,
Placebo to VGCV
Clinical Study Identifier
Merck Sharp & Dohme Corp.
Last Modified on
18 January 2021
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.